1051 related articles for article (PubMed ID: 28403786)
1. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
2. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.
Zhang JC; Chen WD; Alvarez JB; Jia K; Shi L; Wang Q; Zou N; He K; Zhu H
Acta Pharmacol Sin; 2018 Nov; 39(11):1693-1698. PubMed ID: 29991709
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Bastiaannet E; Battisti N; Loh KP; de Glas N; Soto-Perez-de-Celis E; Baldini C; Kapiteijn E; Lichtman S
J Geriatr Oncol; 2019 May; 10(3):389-397. PubMed ID: 30025821
[TBL] [Abstract][Full Text] [Related]
4. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Friedman CF; Postow MA
Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
[TBL] [Abstract][Full Text] [Related]
5. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
6. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Quagliariello V; Passariello M; Bisceglia I; Paccone A; Inno A; Maurea C; Rapuano Lembo R; Manna L; Iovine M; Canale ML; Scherillo M; Ascierto PA; Gabrielli D; De Lorenzo C; Maurea N
Front Cardiovasc Med; 2024; 11():1232269. PubMed ID: 38322766
[TBL] [Abstract][Full Text] [Related]
9. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Zhang J; Medeiros LJ; Young KH
Front Oncol; 2018; 8():351. PubMed ID: 30250823
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 inhibitors in the pipeline: Promise and progress.
Vanella V; Festino L; Strudel M; Simeone E; Grimaldi AM; Ascierto PA
Oncoimmunology; 2017; 7(1):e1365209. PubMed ID: 29296516
[TBL] [Abstract][Full Text] [Related]
13. Clinically Approved Monoclonal Antibodies-based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care.
Al-Taie A; Sheta N
Clin Ther; 2024 Jan; 46(1):e29-e44. PubMed ID: 37932154
[TBL] [Abstract][Full Text] [Related]
14. Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events.
Makunts T; Grabska S; Grabski H; Abagyan R
medRxiv; 2024 Feb; ():. PubMed ID: 38405974
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.
Zabeti Touchaei A; Vahidi S
Cancer Cell Int; 2024 Mar; 24(1):102. PubMed ID: 38462628
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; ():. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in small cell lung cancer.
Pakkala S; Owonikoko TK
J Thorac Dis; 2018 Feb; 10(Suppl 3):S460-S467. PubMed ID: 29593891
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.
Gellrich FF; Schmitz M; Beissert S; Meier F
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31947592
[TBL] [Abstract][Full Text] [Related]
19. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma.
Kassardjian A; Moatamed NA
Int J Clin Exp Pathol; 2021; 14(10):1038-1047. PubMed ID: 34760040
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in clinical trials.
Sharon E; Streicher H; Goncalves P; Chen HX
Chin J Cancer; 2014 Sep; 33(9):434-44. PubMed ID: 25189716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
